DX600 TFA
Based on 4 publication(s) in Google Scholar
DX600 TFA is a selective ACE2 specific inhibitor (KD: 1.3 nM), and does not cross-react with ACE. DX600 TFA exacerbates diabetes-induced cardiovascular dysfunction and the increase in cardiac and renal NOX activity.
For research use only. We do not sell to patients.
- Purity : 99.20%
- Formula: C141H185N35O40S2.xC2HF3O2
- Molecular Weight:3074.33 (free acid)
-
Storage:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) DX600 TFA
More
Biological Activity
Description
In Vitro
DX600 (1 μM) TFA inhibits rhACE2 activity by 47%, with a pIC50 of 8.0[4].
DX600 (10 μM) TFA inhibits ACE2 activity by 42% in human MNCs (mononuclear cells)[4].
DX600 (100 nM, 4 h) TFA decreases NR 8383 cell growth and increase in TNF-a and IL-6 content in the supernatant (in the presence of LPS and osthole)[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
DX600 (0.1 µmol/L/kg, i.v ) TFA increases thrombus weight by 30% in thrombosis model in rats[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:STZ-treated diabetes rats[2]
-
Dosage:5 μg/kg/day
-
Administration:i.p., daily for 4 weeks
-
Result:Increased cardiac and renal NOX activity.
Chemical Information
-
Appearance Solid
-
Molecular Weight 3074.33 (free acid)
-
Formula C141H185N35O40S2.xC2HF3O2
-
Color White to off-white
-
Sequence
Ac-Gly-Asp-Tyr-Ser-His-Cys-Ser-Pro-Leu-Arg-Tyr-Tyr-Pro-Trp-Trp-Lys-Cys-Thr-Tyr-Pro-NH2 ( Disulfide bridge: Cys6-Cys17)
-
Sequence Shortening
Ac-GDYSHCSPLRYYPWWKCTYPDPEGGG-NH2 ( Disulfide bridge: Cys6-Cys17)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry. [Abstract]2022 Mar 1;34(3):424-440.e7. PMID: 35150639 -
-
J Agric Food Chem
Activation of ACE2 by Hazelnut-Derived Peptide YYLLVR: A Novel Strategy against Hypertension-Induced Cognitive Impairment. [Abstract]2026 Jul 29;74(29):22889-22907. PMID: 42446599 -
J Agric Food Chem
Hazelnut-Derived Peptide YYLLVR Improves Endothelial Dysfunction in Hypertension by Activating ACE2. [Abstract]2025 Jul 9;73(27):17024-17039. PMID: 40522957
Solvent & Solubility
In Vitro:
H2O : 100 mg/mL (Need ultrasonic)
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Liao K, et al. Development of an enzymatic assay for the detection of neutralizing antibodies against therapeutic angiotensin-converting enzyme 2 (ACE2).J Immunol Methods. 2013 Mar 29;389(1-2):52-60. [Content Brief]
[2]. Yousif MH, et al. Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes. Pharmacol Res. 2012 Sep;66(3):269-75. [Content Brief]
[3]. Svilenov HL, et al. Extrinsic stabilization of antiviral ACE2-Fc fusion proteins targeting SARS-CoV-2. Commun Biol. 2023 Apr 8;6(1):386. [Content Brief]
[4]. Joshi S, et al. Angiotensin converting enzyme versus angiotensin converting enzyme-2 selectivity of MLN-4760 and DX600 in human and murine bone marrow-derived cells. Eur J Pharmacol. 2016 Mar 5;774:25-33. [Content Brief]
[5]. Fraga-Silva RA, et al. ACE2 activation promotes antithrombotic activity. Mol Med. 2010 May-Jun;16(5-6):210-5. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DX600 TFA Related Classifications
HY-P2222A Related Classifications
Powered by Bioz